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Abstract
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broadly neutralizing
antibodies 2F5 and 4E10. To date, no immunization regimen in animals or humans has produced HIV-1 neutralizing MPER-
specific antibodies. We immunized llamas with gp41-MPER proteoliposomes and selected a MPER-specific single chain
antibody (VHH), 2H10, whose epitope overlaps with that of mAb 2F5. Bi-2H10, a bivalent form of 2H10, which displayed an
approximately 20-fold increased affinity compared to the monovalent 2H10, neutralized various sensitive and resistant HIV-
1 strains, as well as SHIV strains in TZM-bl cells. X-ray and NMR analyses combined with mutagenesis and modeling revealed
that 2H10 recognizes its gp41 epitope in a helical conformation. Notably, tryptophan 100 at the tip of the long CDR3 is not
required for gp41 interaction but essential for neutralization. Thus bi-2H10 is an anti-MPER antibody generated by
immunization that requires hydrophobic CDR3 determinants in addition to epitope recognition for neutralization similar to
the mode of neutralization employed by mAbs 2F5 and 4E10.
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Introduction
The trimeric HIV-1 envelope glycoprotein (Env), composed of
its receptor binding subunit gp120 and the fusion protein gp41, is
the main target for neutralizing antibodies. Although recent
studies have demonstrated the potential of the human immune
system to produce broadly neutralizing antibodies (bnAbs) directed
against gp120 [1–10], generation of antibodies with broad cross-
clade neutralization activity via recombinant Env immunization
has been rare [11–14]. This may be due in part to the long time
frame required to generate such antibodies as well as to multiple
evasive strategies developed by the virus [15–17].
Because Env gp41 contains highly conserved sequences that are
exposed during the conformational changes leading to membrane
fusion [18,19] a considerable effort is underway to target gp41
with a focus on the membrane proximal external region (MPER).
The MPER is recognized by the broadly neutralizing antibodies
(bnAbs) 2F5, Z13, 4E10 and 10E8 [9,20–23]. They interact with
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linear epitopes of the MPER [9,24–26] and gp41-mAb interaction
most likely prevents refolding of gp41 into the six-helical bundle
conformation [27–29]. Notably, 2F5 and 4E10 are among the
broadest cross-reactive human neutralizing antibodies directed
against HIV-1 gp41 while recently-described 10E8 combines this
extensive breadth with substantially increased potency [9,22]. The
potencies of 2F5 and 4E10 are confirmed by their ability to
prevent HIV-1 transmission in rhesus macaques by passive
immunization [30–35].
Numerous studies have been performed with purified gp41
proteins and gp41-derived peptides in an attempt to induce such
antibodies by immunization; however, with very limited success so
far [36–45]. This was partly attributed to the fact that both 4E10
and under some experimental conditions also 2F5 display lipid
binding and potential polyreactivity [46], which may be a special
feature of anti-HIV antibodies [47]. However mAb 10E8 does not
bind lipids and is not polyreactive [9]. 2F5 and 4E10 contain
hydrophobic residues within the third complementarity-determin-
ing region of the heavy chain (CDR H3), which do not contact the
antigen directly, but are required for virus neutralization [48–51].
CDR H3 was suggested to insert into the viral membrane and
extract membrane-embedded MPER leading to tight binding
[52,53]. In addition CDR H3 of 2F5 may function in destabilizing
the helical region downstream of the core 2F5 epitope leading to
the extended-loop conformation of the 2F5 epitope [54]. Both
models are consistent with the finding that neutralization activity
of MPER antibodies depends on the transmembrane region
allowing functional MPER exposure [55]. Furthermore, MPER
antibody epitopes of most primary isolates become only accessible
after receptor/co-receptor-binding induced conformational
changes in Env [56,57]. In addition, MPER mAb Env recognition
was reported to induce gp120 shedding leading to irreversible
neutralization effects [58]. Moreover, MPER antibody epitope
access may be size-restricted [59], which is consistent with the
proposal that such antibodies target the transient fusion-interme-
diate conformational state of gp41 [60] that is also difficult to
access by HR1-specific neutralizing antibodies [61–63]. Accord-
ingly, anti-MPER-like neutralization activity in patient sera was
reported to be rare [64–67] or absent [68,69]. This was attributed
to the fact that MPER-specific antibodies in acutely infected
individuals are polyreactive [70] and their B cells may undergo
clonal deletion [71]. However, a recent study suggested that
10E8-like potent anti-MPER antibodies occur frequently in sera
with high neutralizing breadth and potency without exhibiting
autoreactivity such as lipid interaction [9].
Thus a major challenge remains to induce MPER-specific
neutralizing antibodies upon immunization. Therefore we immu-
nized two llamas with proteoliposomes containing trimeric gp41
consisting of the HIV-1 Env transmembrane region and MPER.
Llamas (Lama glama) and other Camelidae produce classical
antibodies as well as heavy chain-only antibodies [72]. Notably,
VHH (variable domain of the heavy chain of a heavy chain only
antibody) specific for gp120 with broad neutralizing activity have
been successfully produced by immunization before [73–78]. Here
we report the functional and structural characterization of the
llama anti-MPER VHH 2H10. Our data suggest that this is the
first MPER-specific antibody induced by immunization that
employs similar structural features as mAbs 2F5 and 4E10 for
neutralization. 2H10 requires a hydrophobic CDR3 for neutral-
ization but not for interaction with its epitope, like mAbs 2F5 and
4E10. Futhermore, 2H10 binds to a 2F5 overlapping epitope that
is in an alpha-helical conformation, which provides important
insights for the development of MPER based vaccines.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the Dutch
Experiments on Animals Act 1997. In accordance with article 18
of the Act the protocol was assessed and approved by the Animal
Ethics Committee of the Utrecht University (Permit Number:
DEC#2007.III.01.013). All efforts were made to minimize
discomfort related to immunizations and blood sampling. The
animal welfare officers of the Utrecht University checked the
mandatory administration and supervised the procedures and the
well-being of the llamas that were used.
Preparation of gp41 constructs
The HIV-1 gp41 constructs ‘gp41CHRTM’, clade B C-
terminal Heptad Repeat (CHR), MPER and transmembrane
(TM) regions (residues 629–706, HXB2c numbering), ‘gp41-
GCN’, gp41 residues 629–683 (HXB2c numbering) fused to a
trimeric GCN4 leucine zipper [79], and ‘gp41INT’, which has a
similar design as reported [60] with the exception that the trimeric
GCN4 zipper was fused in frame with part of gp41 NHR, were
cloned into pETM-11 (EMBL, Heidelberg) or pETM-13 using
standard PCR techniques. Proteins were expressed in Escherichia
coli strains C41 or BL21. Cells were grown to an OD600 of 0.8 and
induced with 1 mM isopropyl-ß-D-thiogalactopyranoside (IPTG).
Cells were harvested by centrifugation and lysed in either
phosphate buffered saline (PBS) supplemented with 1% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS) or lysed in 20 mM tris(hydroxymethyl)aminomethane
hydrogen chloride (Tris-HCl) pH 8.0, 100 mM NaCl, or in
20 mM Bicine pH 9.3, 100 mM NaCl, for ‘gp41CHRTM’, ‘gp41-
GCN’ and ‘gp41INT’ respectively. Purification was performed
using a Ni2+ affinity or Q-sepharose column (‘gp41INT’) and gel
filtration on a Superdex 200 column (GE Healthcare). Gp41528–
683 was produced as described [29].
Preparation of immunogen
The concentration of gp41CHRTM was adjusted to 1 mg/ml.
Lipids POPC, POPE, POPS, Cardiolipin/Sphingomyelin and
cholesterol (Avanti Polar Lipids) were dissolved in chloroform and
mixed in a 1:2:1:2:5 ratio (w/w). After solvent evaporation, the
lipid film was dried under vacuum. Multilamellar vesicles were
Author Summary
Due to the absence of an effective vaccine or cure for
acquired immunodeficiency syndrome (AIDS), HIV-1 infec-
tions still result in high mortality. Two antibodies, 2F5 and
4E10, previously isolated from HIV-1 infected patients,
prevent infections by binding to the MPER of gp41, a part
of the virus that is difficult to access and only transiently
exposed. Here, we immunized llamas with a gp41-based
immunogen and subsequently isolated a small antibody
fragment (VHH) that can easily access and recognize the
MPER. We showed that a unit of two VHH, named bi-2H10,
was indeed capable of preventing HIV-1 from infecting
cells. We determined the three dimensional structure of
the VHH and mapped its interaction site to an MPER region
that overlaps with the 2F5 epitope. The 2H10 VHH displays
a membrane binding component important for neutrali-
zation that resembles that of 2F5. In conclusion, we have
developed an immunogen and a small antibody that may
have great potential for development of novel anti-HIV/
AIDS vaccines and treatments.
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obtained by resuspending the lipid film in PBS to a final
concentration of 1 mg/ml. After three quick freeze/thaw rounds
the liposome suspension was extruded through a 100 nm
membrane. Liposomes and gp41CHRTM were mixed in a 1:1
ratio (w/w). CHAPS was removed by extensive dialysis with PBS
containing 0.1 mg/ml BioBeads (BioRad), changing the solution
every eight hours for two days. The quality of gp41CHRTM
proteoliposomes was confirmed by dynamic light scattering
(Malvern Nano ZS).
Immunization and construction of phage libraries
Two llamas (L6 and L7) were immunized intramuscularly with
the gp41CHRTM reconstituted in the trimeric form into synthetic
liposomes (gp41 proteoliposomes) without adjuvant. The immu-
nization scheme consisted of a priming immunization at day 0
followed by 5 boosts, which were given at days 7, 14, 21, 28 and
35. During the prime and the first boost 0.25 mg of gp41 and
0.5 mg of lipids were used per injection. These amounts were
halved for the remaining boosts. Importantly no adjuvants were
used. The immune response was measured in the serum taken at
day 21 and compared to day 0. At day 43 lymphocytes were
collected from the two llamas for construction of two separate
phage libraries, as described previously [80]. The genes encoding
for the VHH were amplified and cloned in the phage-display
plasmid, pAX50. The plasmids were transferred to E. coli strain
TG1 [supE hsdD5 thi D(lac-proAB) F9(traD36 proAB+,lacIq
lacZDM15)].
Selection of gp41-specific VHH
Two rounds of selection with phage libraries were carried out by
panning phages onto gp41-proteoliposomes immobilized in
microtiter plate wells. In the first round selection, gp41
proteoliposomes at 5, 1 and 0.2 mg were coated in the wells of
PolySorp (Nunc) microplate overnight at 4uC followed by PBS
containing 4% Marvel dried skimmed milk (Premier International
Foods UK Ltd) for one hour at room temperature. approximately
1010 of the phages, pre-incubated for 30 minutes in 2% skimmed
milk in PBS and empty liposomes to reduce nonspecific binding,
were then added to the wells for 2 hours followed by extensive
washing (15 times) with PBS containing 0.05% Tween 20 (PBS-
T)(the 5th, 10th and 15th wash steps were done for 10 min) and
three times with PBS. The bound phages were eluted with
100 mM TEA, neutralized with 1 M Tris-HCl pH 7.5, and
rescued by infection of the E. coli strain TG1, which were then
plated on LB agar plates containing 100 mg/ml ampicillin and 2%
glucose. The phages eluted from 1 mg coated gp41 proteolipo-
somes in the first round yielded the highest enrichment of ,100
times. These were therefore chosen for further selection in a
second round. The selected polyclonal phages were amplified in E.
coli strain TG1 after infection with helper phages VCSM13
(Stratagene). After purification from the culture supernatant,
phages were used as input for the second round selection. Lower
concentrations of proteoliposomes (0.5 and 0.1 mg per well) were
coated. ,109 phages of the amplified phages were incubated in
each well. After extensively washing away unbound phages, the
bound phages were eluted by 100 ml of 150 mg/ml human
monoclonal antibodies of either 2F5 or 4E10. TG1 cells were
infected with the eluted phages. The infected TG1 cells were
grown on LB agar plates containing 100 mg/ml ampicillin and 2%
glucose to obtain individual colonies. The infected TG1 were also
spotted on the LB agar plates supplemented with 100 mg/ml
ampicillin and 2% glucose for the assessment of the efficiency of
the selection. The enrichment of specific phages was estimated in
comparison with the phages that were eluted by an irrelevant
human monoclonal antibody (Remicade, Schering-Plough) or with
the phages eluted from the empty wells. DNA inserts of a number
of selected phages binding to gp41 were recloned to plasmid
pAX51 using the restriction sites SfiI and BstEII.
Phage ELISA
MaxiSorp (Nunc) plate wells were coated overnight at 4uC, with
gp41-GCN in PBS. After blocking of the wells with 4% skimmed
milk in PBS, they were incubated with VHH fused to M13 phages
in the presence of 2% skimmed milk. The wells were washed with
PBS-T, and bound phages were detected by incubation with a
mouse monoclonal antibody against M13 phage coupled to horse
radish peroxidase (HRP). The amount of HRP was visualized by
the addition of O-phenylenediamine (OPD) supplemented with
0.03% H2O2. The reactions were stopped by the addition of 1 M
H2SO4 and the optical density was measured at 490 nm.
Production and purification of gp41-specific VHH
TG1 strains expressing monoclonal VHH were cultivated in
26YT medium supplemented with 100 mg/ml of ampicillin until
the optical density of culture medium reached 0.5 at 600 nm.
Then 1 mM IPTG was added to induce VHH production for
5 hours at 37uC. VHH were extracted from the periplasmic
fraction and bound to Talon metal-affinity resin (Clontech
635504). After washing away unbound material, the bound
VHH were eluted by 300 mM imidazole in PBS. The eluted
VHH were dialyzed against PBS with two buffer changes. The
VHH were dialyzed twice for 1.5 hours at room temperature,
followed by dialysis overnight at 4uC. The VHH were analyzed on
15% acrylamide sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) stained by Coomassie Brilliant Blue
and a Western blot using the antibody against the myc-tag (9E10).
Binding of VHH to HIV-1 envelope proteins in ELISA
The binding of the VHH to HIV-1 envelope was performed on
the immobilized gp41 and gp140-92UG037 in the microtiter plate
(MaxiSorp from Nunc) in ELISA. 200 ng Gp41-GCN or 280 ng
gp140-92UG037 protein were coated in the wells of microtiter
plates overnight at 4uC followed by incubation with 4% skimmed
milk to block non-specific binding. Dilution series of purified VHH
were incubated with the coated wells for one hour at room
temperature followed by the removal of unbound VHH by
washing three times with PBS-T and one time with PBS. Bound
VHH were detected with anti-myc tag antibody (9E10) and
donkey anti mouse peroxidase (DAMPO). The antibodies were
incubated for one hour and washed with PBS-T and PBS between
each incubation. The plates were developed using OPD contain-
ing 0.03% H2O2. The reaction was stopped with 1 M H2SO4.
The optical density was measured at 490 nm.
Binding of VHH to membrane anchored Env
Titrating amounts of antibodies were added to JR-FL HIV-1
Env-transfected 293T cells expressing either cleaved or uncleaved
Env, incubated for 1 h at 37uC and washed with FACS buffer
(PBS, 5% heat-inactivated fetal calf serum [HIFBS], 0.02% azide).
MAbs b6, b12, and 4E10 were detected with a secondary anti-IgG
Ab conjugated to phycoerythin (Jackson ImmunoResearch). MAb
b12 and the VHH 2H10, bi-2H10 and bi-2H10 W100A were
biotinylated and detected with streptavidin PE. MAb b6 binding is
weak on cleaved Env, confirming that most Env is cleaved [81].
Binding was analyzed using flow cytometry, and binding curves
were generated by plotting the mean fluorescence intensity of
antigen binding as a function of antibody concentration.
HIV-1 Neutralizing Anti-gp41 VHH
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Bivalent VHH construction
PCR was used to amplify the VHH sequences. Different primer
sets designed to amplify the VHH that will be located at the N
terminus and the VHH that will be located at the C terminus of
the bivalent VHH. The primers at the 39 of the N-terminal VHH
and at the 59 of the C-terminal VHH, may encode a flexible
sequence glycine-serine (GS) linker represented by a repeat of the
pentapeptide ‘‘G-G-G-G-S’’, also called 5GS. These same primers
contain a unique restriction site (BamHI). We constructed bi-2H10
with 5GS, 15GS, and 25GS linkers and with the linker
GGGGSGGGGSGGGGGGS, called 17GS. For the studies we
used the bi-2H10 with the 17GS linker, unless specified differently.
After PCR amplification, the generated fragments were cleaved at
a unique N-terminal restriction site (SfiI restriction site) and BamHI
for the VHH that will be located at the N terminus, and with
BamHI and at a unique C-terminal restriction site (BstEII) for
VHH that will be located at the C terminus. The fragments are
ligated into pAX51, which was digested with SfiI and BstEII.
Lipid binding assays
Antibodies were mixed with liposomes having the lipid
composition as described above in PBS and their buffer was
adjusted to 40% sucrose. The 40% sucrose mixture was overlaid
stepwise with 30, 20, 10 and 5% sucrose and centrifuged in a Ti55
swinging bucket rotor for 18 h at 50 K rpm. Six fractions were
recovered from the gradient and samples thereof were analyzed by
SDS-PAGE.
For ELISA analysis, cardiolipin from bovine heart (SIGMA,
C0563) and l-a-phosphatidyl-l-serine from bovine brain (SIGMA,
P7769) were dissolved in ethanol to a concentration of 5 mg/ml
and further diluted with PBS to 50 mg/ml of which 100 ml was
coated per well in PolySorp plates (Nunc) overnight at room
temperature without a cover foil to allow complete evaporation of
the sample. As a control gp140-92UG037 was coated on a
MaxiSorp plate (Nunc). Dilution series were prepared of 2H10, bi-
2H10, 2F5 and 4E10. 2F5 and 4E10 were detected with the mouse
anti-human IgG monoclonal 3E8 (SANTA CRUZ). The rest of
the ELISA was performed as described above.
Viruses
HIV-1 IIIB was obtained from the Centralised Facility for AIDS
Reagents (CFAR), NIBSC and propagated in H9 cells. Replication-
competent NL43 stocks were prepared from a replication-compe-
tent HIV-1 molecular clone by transfection of 293T cells. All other
used HIV-1 viruses were HIV-1 envelope pseudotyped viruses and
were produced in 293T cells by co-transfection with the pSG3Denv
plasmid and the relevant envelope plasmid. The subtype B HIV-1
reference panel of envelope clones and the subtype C clones were
obtained through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH, USA. AC10.0 clone 29
and SC422661 clone 8 were contributed by David Montefiori, Feng
Gao and Ming Li; ZM109F.PB4 was contributed by David
Montefiori, Feng Gao, S Abdool Karim and G Ramjee;
RHPA4259 clone 7 was contributed by B.H. Hahn and J.F.
Salazar-Gonzalez. The SHIV clones were constructed at the BPRC
by Zahra Fagrouch and Ernst Verschoor. The panel of transmitted
subtype B (T/F) clones (WEAU-d15.410.787, 1006-11.C3.1601,
1054-07.TC4.1499, 1056-10.TA11.1826, 1012-11.TC21.3257)
were provided by George Shaw and Beatrice Hahn.
Cells
TZM-bl cells were obtained through the NIH AIDS Research
and Reference Reagent Program from J. C. Kappes, X. Wu, and
Tranzyme, Inc., and cultured in Dulbecco’s modified Eagle
medium (Invitrogen) containing 10% (v/v) fetal calf serum (FCS).
Neutralization assay
Neutralization was measured using pseudovirus or 200 50%
tissue culture infective doses (TCID50) of virus in the TZM-bl cells
as targets following the methods of Derdeyn et al. [82] Wei et al.
[83] and Li et al. [84], with Bright-Glo luciferase reagent
(Promega, Southampton, UK). The neutralization activity of each
VHH was assayed in duplicate. No virus inactivation was observed
with a negative control VHH. VHH IC50 titers were calculated
using the XLFit4 software (ID Business Solutions, Guildford, UK).
The HIV-1 neutralization potency of llama 6 & 7 serum/plasma
samples were also evaluated in TZM-bl. Neutralization was
measured using 200 TCID50 of IIIB virus in the TZM-bl cell-
based assay, as described above, using a Glomax plate reader
(Promega). Serum samples were heat-inactivated to inactivate
complement by incubation at 56uC for 1 h before use in
neutralization assays. Threefold serial dilutions of llama sera were
then tested, starting at a 1:5 dilution.
Epitope mapping
The binding of VHH and mAb to peptides was assessed in a
Pepscan-based ELISA [85]. Structural aspects of antibody antigen
interaction were revealed through small random peptide libraries
[86]. Each VHH and mAb was titrated to ensure that optimal
binding was achieved and that nonspecific binding was avoided.
Each well in the card contained covalently linked peptides that
were incubated overnight at 4uC with VHH and mAb, between 1
and 10 ng/ml in PBS containing 5% horse serum (v/v), 5% OVA
(w/v), and 1% (v/v) Tween 80, or in an alternative blocking buffer
of PBS containing 4% horse serum (v/v), and 1% (v/v) Tween 80.
After washing, the plates were incubated with a HRP-linked rabbit
anti-Ab (DakoCytomation) for 1 h at 25uC. After further washing,
peroxidase activity was assessed using substrate (0.5 g/l 2,29-azino-
di[3-ethyl-benzthiazolinesulfonate(6)]diammonium salt (ABTS))
with 0.006% H2O2 in 0.18 M Na2HPO4, 0.22 M citric acid was
added until the solution had a pH of 4. The color development
was quantified after 60 minutes using a charge-coupled device
camera and an image-processing system.
Protein expression and purification of 2H10 for
crystallization
The cDNA corresponding to 2H10 was synthesized (GeneArt)
and cloned into vector pMEK220 (without 6his-tag or myc tag)
and 2H10 was expressed in E. coli strain BL21gold (DE3)
(Invitrogen). Cells were grown to an OD600 of 0.7 and induced
with 1 mM IPTG at 37uC. After 5 hours cells were harvested by
centrifugation and lysed by sonication in 0.02 M 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES), 0.1 M NaCl,
pH 7.4 (HEPES buffer). 2H10 was purified by affinity chroma-
tography using a Protein A column (Roche). 2H10 was eluted with
0.01 M glycine, pH 2.5, and fractions containing 2H10 were
neutralized with 1 M Tris-HCl, pH 8. These fractions were
further purified by gel filtration on a Superdex 200 column (GE
Healthcare) in HEPES buffer. Purity of the sample was confirmed
on a 12% SDS-Tris-Tricine gel.
Crystallization, data collection and structure
determination
2H10 in complex with peptide 903 was subjected to crystalli-
zation at a concentration of 12 mg/ml. Crystals were obtained by
the vapor diffusion method in hanging drops, with equal volumes
HIV-1 Neutralizing Anti-gp41 VHH
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of antibody and reservoir solution (0.1 M Bicine, 3.2 M NH4SO4,
pH 9). The crystal was cryo-cooled at 100 K in reservoir buffer
containing 25% (v/v) glycerol. A complete dataset was collected at
the ESRF (Grenoble, France) beamline ID14-4. Data were
processed and scaled with MOSFLM [87], and SCALA [88].
The crystals belong to space group I23 with unit cell dimensions of
a = 89.95 A˚, b = 89.95 A˚, c = 89.95 A˚ and a= 90.00u. The struc-
ture was solved by molecular replacement using PHASER [89]
and the VHH structure from Protein Data Bank (PDB) ID 3EZJ as
a search model. An initial model was built with ARP/wARP [90]
and completed by several cycles of manual model building with
Coot [91] and refinement with refmac [92] using data to 1.3 A˚
resolution. The final model contains 2H10 residues 1–122.
Molecular graphics figures were generated with PyMOL (W.
Delano; http://www.pymol.org). Coordinates and structure fac-
tures have been deposited in the Protein Data Bank with accession
ID 4B50.
NMR analyses of 2H10 and 2H10 in complex with its
peptide epitope
A 13C,15N-labeled protein sample was prepared at a concen-
tration of 0.95 mM in 20 mM HEPES buffer and 75 mM NaCl at
pH 6.7 with 10% D2O. For the study of the peptide:2H10
complex, a solution of gp41 peptide (655KNEQELLELDK-
WASL669.) was prepared at 7.9 mM in the same HEPES buffer
and 5 ml were added step by step to the 13C,15N-labeled protein
sample. A final protein:peptide ratio of 1:1.5 was obtained and 15N
HSQC experiments were recorded for each peptide addition in
order to control the complete disappearance of the free form.
Sequential backbone resonance assignments of free and peptide
bound 2H10 were performed by recording series of 3D
experiments using the BEST scheme (HNCO, HNCA, HNco-
CACB, HNCACB) and the BEST-TROSY scheme (hNcocaNH,
hNcocaNH) [93].
All NMR experiments were performed at 37uC on Agilent
VNMRS 600 or 800 MHz spectrometers equipped with triple-
resonance (1H, 13C, and 15N) coldprobes and shielded z-gradients.
NMR data were processed with NMRPipe [94] and analyzed
using the CcpNmr Analysis routines of CCPN [95]. Chemical
shifts were referenced with respect to the H2O signal at 4.66 ppm
relative to DSS, using the 1H:X frequency ratios of the zero point
according to Markley et al. [96].
Surface plasmon resonance
Surface plasmon resonance (SPR) analysis was performed with a
Biacore T100 (GE Healthcare). As a flow buffer 10 mM HEPES,
150 mM NaCl, pH 7.4 with 0.005% Tween-20 was used. Gp140-
92UG037 was immobilized to 1500 response units using 50 mg/ml
protein in flow buffer on an activated CM-5 sensor chip (GE
Healthcare: BR-1000-50) according to the manufacturer’s instruc-
tions. Specific binding to the target protein was corrected for
nonspecific binding to the deactivated control channel. The flow
rate was 30 mL/min. Regeneration of the sensor chip was
achieved with 4 M MgCl2 for 60 seconds at 50 mL/min. Single
concentration injections were all performed with 100 nM of VHH
for 60 seconds each. All data were measured in duplo and the
curves superpose quite well. Data were analyzed with the Biacore
T100 software version 2. Curves obtained for 2H10 could not be
fitted well with the 1:1 Langmuir or heterogeneous ligand
algorithms, but only with the two-state reaction algorithm. To
establish whether 2H10 indeed binds with a two-state reaction, we
injected 2H10 with different injection durations. This clearly
showed that the dissociation rate is dependent on the injection
time. The longer the duration of the injection, the stronger the
interaction becomes and the dissociation rate decreases. We,
therefore, fitted the curves belonging to the monovalent 2H10
VHH with the two-state reaction model. Curves of the bivalent
2H10 should be fitted with a combination of two-state reaction
and bivalent analyte model, but due to a lack of availability of this
model, the curves were fitted with the heterogeneous ligand fit and
the two-state reaction fit.
Additional SPR analysis was performed using a Biacore 3000
(GE Healtcare). As a flow buffer 10 mM HEPES, 150 mM NaCl,
pH 7.4, 50 mM EDTA with 0.005% P-20 (GE Healthcare) was
used. Gp41INT or gp41528–683 was immobilized to 1000 response
units in a sodium acetate buffer, pH 4.5, on an activated CM-5
sensor chip according to the manufacturer’s instructions. Specific
binding to the target protein was corrected for nonspecific binding
to the deactivated control channel. The flow rate was 20 ml/min.
Regeneration of the sensor chip was achieved with 25 mM NaOH
for 30 seconds at 50 ml/min. Data were analyzed with the
BIAevalution software version 4.1. The curves for 2H10 and
2H10-W100A on gp41INT were fitted with separate association
and dissociation, because global fittings, either 1:1 langmuir or
two-state reaction, did result in reasonable Chi2 scores and
residuals.
Isothermal titration calorimetry
Isothermal Titration Calorimetry (ITC) measurements were
carried out at 25uC on a VP-ITC microcalorimeter (MicroCal).
Both 2H10 and peptides were purified or dissolved, respectively, in
a solution containing 20 mM HEPES, pH 7.4 and 100 mM NaCl.
The samples were degassed for 20 min and centrifuged to remove
any residuals prior to the measurements. The concentration of
2H10 in the sample cell was 10 mM and that of peptide 903 or 904
in the syringe was approximately 100 mM. The peptides injected
into buffer alone was used as a negative control. Data were fit to a
single binding site model and analyzed using Origin version 5
(MicroCal) software.
Site directed mutagenesis
Site directed mutagenesis was performed by PCR with
complementary oligos which carried the desired mutation, to
amplify the whole plasmid. The oligo’s were designed to be
between 42–50 nucleotides long and have a melting temperature
(salt adjusted, calculated on http://www.basic.northwestern.edu/
biotools/oligocalc.html) of approximately 80uC. The PCR reac-
tion was performed with 20 ng of template DNA (2H10-wild type
plasmid), 125 ng each primers, 2 mM DNTPs, Pfu buffer with
2 mM, MgSO4 and 0.5 units of Pfu polymerase (Fermentas). The
protocol consisted of an initial denaturation step at 95uC for 5 min
followed by 16 cycles of 95uC for 30 seconds, 60uC for 1 minute
and 68uC for 7 minutes, and a final step extension at 68uC for
10 min. DNA was cleaned with PCR Clean-up kit (Macherey-
Nagel). Parental methylated DNA was digested with DpnI
(Fermentas), followed by transformation into TG1 E. coli cells.
Modeling of the gp41 peptide interaction with 2H10
Models of gp41 peptide docked onto 2H10 were built with the
webserver version ‘‘The HADDOCK web server for data-driven
biomolecular docking’’ of HADDOCK2.1 [97] using CNS1.2 [98]
for the structure calculations. The coordinates of 2H10 were taken
from the crystal structure, and the gp41 peptide coordinates were
based on those of the helical peptide (653-QEKNEQELLELDK-
WASL-669) from the crystal structure of a late fusion intermediate
of HIV-1 gp41 (PDB code: 2X7R [29]). Ambiguous interaction
restraints were defined, based on the NMR chemical shift
perturbation (CSP) mapping using the program SAMPLEX [99]
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and the epitope mapping. The SAMPLEX program takes as input
a set of data and the corresponding three-dimensional structure
and returns the confidence for each residue to be in a perturbed or
unperturbed state. Residues 47–51, 57–62 and 95–99 identified as
perturbed in 2H10 upon binding to gp41 and residues 657, 658,
661, 662 and 665 identified from the epitope mapping, were used
as interaction restraints for docking. Phi-psi angles were deduced
from the 13C chemical shifts using TALOS+ [100] and the
resulting dihedral and H-bond restraints were used in the
modeling as well. The docking was performed with default
HADDOCK parameters, except that random removal of
restraints was turned off and the clustering cutoff was decreased
to 2.5 A˚ because of the small size of the peptide. Non-bonded
interactions were calculated with the OPLS force field using a
cutoff at 8.5 A˚. The electrostatic potential (Eelec) was calculated by
means of a shift function, while a switching function – between 6.5
and 8.5 A˚ – was used for the Van der Waals potential (Evdw). The
HADDOCK score is used to rank the generated models. It
consists of a weighted sum of intermolecular electrostatics, Van der
Waals, desolvation (DGsolv) [101] and ambiguous interaction
restraint (AIR) energies, defined as: Haddock Score= 0.2Eelec
+1.0EVdW+1.0EDGsolv+0.1EAIR
Results
Immunization of llamas, library construction and
selection of VHH against gp41
Two llamas (L6 and L7) were immunized with the gp41
proteoliposomes composed of an HIV-1-like lipid envelope [102]
and membrane-anchored gp41CHRTM (Fig. 1). The presence of
anti-gp41CHRTM proteoliposome antibodies in the plasma was
confirmed by ELISA at day 21 post immunization. However, no
significant neutralization was detected in the sera/plasma at day
21 and 43 compared to those of day 0. Two phage display libraries
were constructed and the selection of VHH targeting gp41 was
performed in two rounds by direct panning of the phage display
library on immobilized gp41 proteoliposomes. In the first round
triethyl-amine (TEA) was used to elute the phages. In the second
round a specific competitive elution with bnAbs 2F5 or 4E10 was
performed. Monoclonal VHH expressing TG1 clones from first
and second round selections were screened for binding to
detergent-solubilized gp41CHRTM and gp41-GCN (with
pIIGCN in place of the transmembrane region) by phage ELISA.
Approximately 80% of all monoclonal VHH displaying phages
were positive for binding. In order to find VHH targeting specific
binding sites, a competition ELISA between phages and bnAb 2F5
or 4E10 was performed. The phages with either strong binding
signals, and/or binding signals that were inhibited by bnAb 2F5 or
4E10 were chosen for further investigation with purified VHH.
Using ELISA, three of the VHH were found to bind to gp41-
GCN, gp41 proteoliposomes and gp140-92UG037. 2H10, which
originated from llama 7 (L7), exhibited the highest maximum
signal and was therefore chosen for the subsequent studies (see
Fig. 2 for the sequence of 2H10). 2H10 competed for binding to
gp41 with 2F5, but not with 4E10.
Epitope mapping of 2H10 with Pepscan analysis
To determine the epitope of 2H10, its binding to a set of
overlapping linear and cyclic peptides covering the gp41 MPER
was measured. The best binding cyclic 15-mer peptide covered the
gp41 region from amino acid 655 to 669 (655KNEQELLELDK-
WASL669). This peptide was used as a seed for a library in which
the amino acids on each position of the peptide was substituted by
all other 19 natural amino acids. Probing this library with 2H10
and 2F5 Fab allowed the mapping of the 2H10 epitope and
identified five residues (E657, Q658, L661, E662 and K665)
important for 2H10 binding. Notably, three out of the five are part
of the 2F5 epitope (Fig. 3A and 3B).
Next, we tested whether 2H10 recognizes its epitope in a helical
conformation. To achieve this, the peptide sequence (residues
655–669) was fused to a short coiled-coil that was shown to favor a
helical conformation of the fused sequences [103]. The fusion
construct was designed in such a way that the 2H10 residues
required for interaction are exposed. Binding assays demonstrated
that 2H10 binding was unaffected when the MPER peptide was
fused to the coiled-coil template (Fig. 3C). In contrast, 2F5, which
binds its epitope in a b-hairpin conformation [24] shows a
dramatically reduced binding to the coiled-coil MPER construct
(Fig. 3D). Replacement of heptad positions by Gly, which are helix
breakers and thus do not support a helical MPER conformation,
further leads to the loss of 2H10 interaction (Fig. 3C).
2H10 binding to Env and construction of bivalent 2H10
Because MPER antibodies primarily target the fusion interme-
diate state of gp41 [60,104,105], binding of 2H10 was tested to a
soluble form of the fusion intermediate conformation of gp41,
Figure 1. The gp41CHRTM antigen used for immunization.
A) Schematic representation of gp41 and of the regions present in
gp41CHRTM. FP, fusion peptide; HR1, N-terminal heptad repeat; C-C
loop, cysteine loop, HR2, C-terminal heptad repeat; MPER, membrane
proximal external region; TM, transmembrane region. The residue
numbers at the domain/region boundaries are given. B) Gel filtration
chromatogram of recombinant gp41CHRTM, which elutes at 13.3 ml
from the column, similar to the elution profile of a marker protein of
158 kDa. This indicates that gp41CHRTM is most likely trimeric and may
have an elongated structure. The inset shows a Coomassie stained SDS-
PAGE gel with the gp41CHRTM protein band at the left and a protein
marker at the right with the marker protein sizes in kDa indicated at the
right.
doi:10.1371/journal.ppat.1003202.g001
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gp41INT [60]. SPR measurements revealed a KD of 29 nM for the
2H10 monohead (Fig. S1A). The avidity increased substantially to
2.5 nM, when two 2H10 VHH were linked with a 15-GS linker
(bi-2H10) (Fig. S1B). Surprisingly, 2H10 and bi-2H10 interacted
with similar affinities of 18 nM and 1.1 nM, respectively with
gp41523–883, a potential late fusion intermediate conformation [29]
(Figs. S1C and S1D). In addition binding to gp140 from clade
92UG037 was recorded. 2H10 interaction with gp140 was fit with
a two state reaction model, because an experiment with different
injection durations with 2H10 indicated that it binds in two states,
a low affinity followed by a high affinity state (Fig. S1E), which
may be due to heterogeneous conformational states of gp41
present in recombinant gp140 consistent with the presence of non-
native Env on virions [106]. Again the affinity of 2H10
(KD = 4 nM) is inferior to bi-2H10 binding (KD = 0.15 nM), based
on both the heterogeneous ligand fit and the two state reaction fit
(Figs. S1F and S1G). In order to confirm the pepscan 2H10
binding to the linear gp41 peptide epitope, isothermal titration
calorimetry was used to determine the affinity of 2H10 to linear
and cyclic forms of peptide 655KNEQELLELDKWASL669. This
revealed affinities of 35 nM and 84 nM, respectively, indicating
that cyclisation of the peptide epitope is unfavorable and reduces
the binding affinity. However, the KD of 35 nM is in good
agreement with the SPR data and indicates that no other
determinants of gp41 (present in gp41int) contribute to binding.
We next tested whether 2H10 interacts with wild type native Env
expressed on the plasma membrane, which revealed no interaction
with either cleaved or uncleaved forms of JR-FL Env comparable
to the lack of significant 4E10 interaction (Fig. 4). We conclude
that 2H10 interacts with a linear sequence with a helical
conformation present in two gp41 conformations tested.
Bi-2H10 neutralizes HIV-1
The 2H10 VHH monohead did not neutralize any of the HIV-
1 strains tested (Table 1). However, bivalent 2H10, which showed
an increased affinity for gp41 as compared to the monohead, was
able to neutralize HIV-1 isolates and pseudoviruses in a TZM-bl
assay. No substantial difference was observed for bi-2H10 with a
15 or 17 amino acid linker. The activity of bi-2H10 with the 17
amino acid linker (bi-17GS) was mainly directed towards clade B,
neutralizing 14 of 26 B isolates, one clade A (i.e. 92UG037) and
none of the clade C isolates due to the sequence conservation of
the epitope. Eight strains neutralized are Tier 1 and seven are Tier
2 viruses. Bi-2H10 also neutralized both the neutralization
sensitive and resistant variants of SHIV SF162 consistent with
SF162.LS neutralization (Table 1). The IC50 values were between
equal to and 100-fold lower than those of mAb 2F5, which
neutralized 18 out of 23 clade B viruses tested (Table 1). Bi-2H10,
like 2H10, did not interact with cell surface expressed JR-FL Env
(Fig. 4), although the virus was neutralized. We conclude that that
bi-2H10 acts downstream of receptor-induced conformational
changes in Env and the increased avidity of bi-2H10 renders the
VHH neutralization active.
2H10 exposes W100 at the tip of CDR3 which is required
for neutralization
To study the interaction of 2H10 with its epitope, several
attempts were made to obtain crystals of 2H10 in complex with
various MPER peptides based on the Pepscan analyses. However,
in each attempt, diffraction quality crystals were obtained that
contained the VHH, but not the peptide. The best 2H10-
containing crystals diffracted to 1.3 A˚ resolution and the structure
was solved by molecular replacement (Table 2). The structure
resembles the framework of known VHH structures [76], with the
major exception that most other VHH structures have CDR3
loops that fold back on the framework of the VHH, whereas the
CDR3 of 2H10 protrudes from the framework of 2H10. However,
it should be noted that its orientation may have been influenced by
crystal contacts. Its most notable feature is the exposure of W100
at the tip of CDR3 (Fig. 5A). CDR3 W100 resembles the presence
of hydrophobic residues within the CDR3 heavy chains of 2F5 and
4E10 [24,25], which are not essential for epitope interaction
although changes in affinity have been reported depending on the
nature of the antigen for some mutants. In contrast, mutations of
hydrophobic CDR3 residues affect the neutralization potency of
these antibodies dramatically [48–50]. Similarly, several 2H10
W100 mutants (i.e. W100A, W100F and W100L) interacted with
gp41INT and gp140 with affinities comparable to wild type 2H10
(Fig. 6A and Fig. S1H), confirming that W100 is non-essential for
epitope interaction. To study whether W100 is required for
Figure 2. Amino acid and DNA sequence of 2H10. A) Amino acid sequence. Secondary structure assignment is based on the crystal structure.
b-strands are depicted as blue arrows. CDR regions are indicated with CDR1 to CDR3 and are underlined. Residues depicted in bold were mutated.
Mutants that still showed binding are shown in green and mutants that do not bind to the antigen anymore are shown in red. B) DNA sequence
alignment of 2H10 with the germline V-gene from which it originated. The asterisks indicate identical nucleotides. The CDR1 and CDR2 coding
regions are underlined. Codons with at least two point mutations are in boldface.
doi:10.1371/journal.ppat.1003202.g002
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neutralization, the W100A mutation was introduced into bi-2H10
(bi-2H10-W100A). SPR confirmed that bi-2H10-W100A binds to
gp140 comparable to wild type bi-2H10 revealing the same
dissociation rate together with a slightly slower on-rate (Fig. 6B).
Although not essential for gp41 interaction, the exchange of W100
to alanine completely abrogated neutralization of most strains.
Four other strains tested showed a reduced potency as evident
from the 4-and 6-fold increased IC50 values for these viruses
(Table 1). In addition, bi-2H10 W100A did not interact with
surface-expressed Env as expected (Fig. 4). We thus conclude that
CDR3 W100 is dispensable for epitope interaction but is essential
for neutralization similar to the role of hydrophobic CDR3 heavy
chain residues present in mAbs 2F5 and 4E10 [48–50]. In order to
map the gp41 binding site on 2H10 the following mutants (S29F,
Figure 3. Epitope mapping of 2H10 and binding to helical peptides. A) The peptide Sym-903 was used for the replacement analysis with 2F5
and 2H10. Underlined cyan colored residues are recognized by the antibodies. B) Full substitution analysis of 2H10 epitope on gp41 MPER. The
binding activity of VHH 2H10 at 2 ng/ml with a peptide is shown as a vertical line proportional to the Pepscan ELISA signal. Each group of 19 lines
corresponds to the replacement set of all residues except cysteine for each amino acid position in the original 15-mer cyclic peptide:
KNEQELLELDKWASL. Within each group of 19 lines the substitutions are in alphabetical order: based on the one-letter amino acid code
(ADEFGHIKLMNPQRSTVWY) and the reactivity of the original nonapeptide is shown as a red line. The peptides contained an N- and C-terminal
cysteine and were cyclised by addition of a T2-CLIPS [115]. These results show that EQ at position 3 and 4 and LE at position 7 and 8 and K at position
11, cannot be replaced by another amino acid without loss of binding and are thus essential for binding 2H10. C) Binding of VHH 2H10 (100 ng/ml)
and D) Mab 2F5 (1 ng/ml) to gp41-MPER peptides grafted in GCN4-like helical templates that contain a stabilizing Ile/Leu heptad repeat (top panel)
and binding to peptides in which the zipper motif is mutated to destabilizing glycine residues (lower panel). Peptide sequences are all based on
hybrids of HIV-1 gp41 and GCN4. Alignment is shown of peptide sequence with heptad repeat positions (top line). Residues essential for 2H10
binding according to the substitution analysis are underlined and residues essential for 2F5 binding are in green. Mutations are shown with one-letter
codes and dots indicated that the residue is not changed.
doi:10.1371/journal.ppat.1003202.g003
HIV-1 Neutralizing Anti-gp41 VHH
PLOS Pathogens | www.plospathogens.org 8 March 2013 | Volume 9 | Issue 3 | e1003202
D53T/R54S, R54S, R56A, R71S, R93A, E95A, R97A) were
designed based on the structure (Fig. 5A) and the VHH germline
sequence of CDR1 and CDR2 (Fig. 2). Assessment of binding by
SPR revealed that the single mutants R56A, R93A, E95A, and
R97A lost binding to gp140-92UG037 (Fig. 6A). All other mutants
(S29F, D53T/R54S, R54S, R71S) still bound gp140, although the
affinities for some seemed to be marginally lower than for wild-
type 2H10. This thus implicates the charged residues R56 in
CDR2 and R93, E95 and R97 of CDR3 in gp41 recognition.
Because it was reported that mAbs 2F5 and 4E10 have lipid
binding activity, we tested whether 2H10 also binds liposomes or
lipids. Sucrose gradient flotation analyses showed that 2H10 does
not float with liposomes having the lipid composition of native
HIV-1 virions. 2H10 is only found in the bottom fractions of the
gradient while a substantial amount of 4E10 floats to the upper
fraction of the gradient in this assay. However, 2F5 did not reveal
any liposome binding either (Fig. S2A). This is consistent with
ELISA data which demonstrated binding of mAb 4E10 to
cardiolipin and phosphatidylserine, while 2H10, bi-2H10 and
2F5 revealed no binding activity (Fig. S2B). We conclude that
2H10 exerts no measurable lipid binding activity.
2H10-gp41 complex formation: NMR characterization of
2H10 in the free and peptide-bound form
15N HSQC spectra of 2H10 were recorded in the absence or
presence of an excess of the gp41 peptide and revealed a sufficient
spectral resolution to allow the 1H,15N, and 13C backbone
assignment of the two forms using heteronuclear experiments (Fig.
S3). Chemical shift index (CSI) calculated from the CB, CA, N
and CO chemical shifts reveal similar secondary structures for the
free and the bound forms (Fig. S4). The specific shift of individual
residues was observed using 15N HSQC spectra recorded at
different ratios of gp41 peptide to 2H10 and depend on the
peptide concentration (Fig. 5B). These data reveal a slow exchange
process between the bound and the free form in agreement with
the affinity constant measured for this complex. The complete list
of chemical shift differences (CSD) induced in 2H10 upon peptide
binding is listed in Figure S5 (Fig. S5), which confirmed further
that peptide binding, did not induce conformational changes in
the tertiary structure of 2H10. Notably most significant CSDs map
to one surface of the 2H10 structure providing a first clue on the
gp41 ligand position (Fig. 5C).
Modeling of the 2H10 gp41 peptide complex
Modeling of the 2H10 interaction with a helical gp41 peptide
conformation with HADDOCK [97] readily produced a top
cluster with an average cluster score significantly lower than any
other solution (296.360.5 a.u.). This cluster corresponded also to
the most populated one with 173 members out of 200 models
generated. Its electrostatic energy is 2437.0631.1 kcal/mol and
its Van der Waals energy 236.966.9 kcal/mol. The model
reveals that the short gp41 helix binds in a parallel fashion to the
2H10 beta-sheet involving a network of salt bridges (E654-K60;
K665-E95; D664-R56) and hydrogen bonds (E654-Q44; E657-
S62 amide; Q658-amide-L47; E662-Y37; R96-L669 carbonyl). In
addition, R93 stabilizes the orientation of Y36 and E95, which
contact E662 and K665, respectively (Fig. 7A). The network of
interactions is consistent with the chemical shift perturbation
(Fig. 5B) and mutagenesis data, which implicate R56, R93, E95
and R97 in the interaction. CDR3 S99 and S100D show
additional chemical shift differences upon peptide binding. This
may indicate that the CDR3 may be flexible enough to contact the
peptide or alternatively, that peptide binding induces major
changes within the CDR3 conformation or orientation. Among
the interacting residues are five of the six framework residues that
deviate from the germline (S35, F50, K60, V61 and R93) by at
least two nucleotide changes in their codons (Fig. 2B). The sixth
residue (L91) is very close to the interaction site. Their occurrence
in VHH is rather rare (F50,1.5% of VHH sequences, K60, 0.8%,
V61, 0.7% and R93, 0.52% of VHH sequences (https://fungen.
wur.nl/). The model also corroborated that CDR3 W100 does not
interact with gp41. Subsequent superpositioning of the Ca atoms
of the VHH-peptide model (Fig. 7A) and the trimeric structure of
the late fusion intermediate [29] yielded a trimer model without
any clashes (Fig. 7B). Importantly, it revealed that the side chain of
W100 is positioned in such a way that it could dip into the
membrane bilayer in the same plane as gp41 MPER residues
W678, W680 and Y681 (Fig. 7B). The latter have been proposed
to insert into the membrane during the conformational changes of
gp41 leading to membrane fusion [29]. We conclude that 2H10
binds a helical epitope of gp41, which allows positioning of the
CDR3 W100 towards the membrane. Due to the small size of the
VHH, 2H10 may stay associated with gp41 until late stages of
membrane fusion.
Discussion
The HIV-1 envelope fusion subunit gp41 contains highly
conserved epitopes within its MPER that are recognized by the
potent and broadly neutralizing antibodies 2F5 and 4E10.
Figure 4. 2H10, bi-2H10 and bi-2H10 W100A do not interact
with membrane anchored Env. FACS analysis of HEK293T cells
transfected with JR-FL Env in its cleaved (A) and un-cleaved form (B).
The increase in mean fluorescence intensity (MFI) has been blotted as a
function of antibody concentration. Control antibodies include b12, b6,
b12-Bio (biotinylated version of B12) and 4E10. The lack of significant b6
interaction with the cells expressing cleaved Env indicates that most
Env has been processed.
doi:10.1371/journal.ppat.1003202.g004
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Although these bnAbs recognize linear epitopes, immunization
with gp41 peptides or proteins has not yet produced such
antibodies [107]. In this study, we isolated and characterized a
VHH from a llama immunized with gp41 proteoliposomes.
Similar gp41 proteoliposomes, with a different liposome formula-
tion and gp41 construct, used in a previous immunization study of
mice using a different immunization strategy, yielded sera with no
significant neutralization [37]. The VHH 2H10 recognizes an
Table 1. 2H10, bivalent 2H10 and mutant bi-2H10 IC50 titers against HIV-1 in TZM-bl cells.
IC50 (mg/ml)
HIV-1/SHIV strain Type Clade Tier
Accession
code Epitope sequence 2H10 bi-15GS bi-17GS
W100A bi-
15GS 2F5
HXB2 PV B 1 K03455 EQELLELDK
BaL.26 PV B 1 DQ318211 EQELLELDK N 6.9 11 N 10
SS1196.1 PV B 1 AY835442 EQELLELDK N 13.5 13 N 15.5
NL4_3 PV B 1 U26942 EQELLELDK N 4.4 0.2 N 0.087
IIIB TCLA B 1 EU541617 EQELLELDK N 9.0 15.7 N 0.4
AC10.0.29 (SVPB13) PV B 2 AY835446 EQELLALDK N N 4.4
RHPA4259.7 (SVPB14) PV B 2 AY835447 EQELLALDK N N 13.46
SF162.LS PV B 1a EU123924 EQELLELDK N 49.02 N 1.77
MN-3 PV B 1 AY669737 EQELLELDK N 0.78 4.80 ,0.02
JR-FL.JB PV B 2 AY669728 EQELLELDK N 2.42 15.01 3.52
6535.3 PV B 2 AY835438 ELELLELDK N N N 5.86
WITO4160.33 PV B 2 AY835451 ELELLELDK N N N 1.05
TRJO4551.58 PV B 3 AY835450 ELELLKLDQ N N N N
REJO4541.67 PV B 2 AY835449 EQELLELDK N N N 1.04
PVO.4 PV B 3 AY835444 EQDLLALDK N N N N
TRO.11 PV B 2 AY835445 EQELLELDS N N N N
CAAN5342.A2 PV B 2 AY835452 EKELLELDK N N N 10.11
THRO4156.18 PV B 2 AY835448 EKELLELDK N 33.48 N N
QH0692.42 PV B 2 AY835439 EHELLELDK N 14.35 N 1.01
SC422661.8 PV B 2 AY835441 EQELLELDK N 10.8
SHIV SF162P4 PV B 1 M65024 EQELLELDK N 29.3
SHIV SF162P3 PV B 2 AY988107 EQELLELDK N 4.4
WEAU-d15.410.787 PV B(T/F) 2 EU289202 EQELLELDK N 4.76 17.21 0.59
1006-11.C3.1601 PV B(T/F) 2 EU289183 ELELLALDK N N N 1.99
1054-07.TC4.1499 PV B(T/F) 2 EU289185 EKELLELDK N N N N
1056-10.TA11.1826 PV B(T/F) 1B EU289186 EQELLELDK N 28.9 N 0.26
1012_11_TC21_3257 PV B(T/F) 1B EU289184 EKELLELDK N N N 0.91
92UG037.A9 MC A ND AB253429 EKDLLELDK N 2.4 28 N
92UG0378 PV A 2 AB253429 EKDLLELDK N 4.66 18.69 0.60
Q23.17 PV A ND AF004885 EKELLELDK N N N 4.97
Q769.d22 PV A 2 AF407158 EQDLLALDK N N N 4.92
0330.v4.c3 PV A ND HM215257 EQDLLALDK N N N 14.10
ZM249M.PL1 PV C 2 FJ496214 EKDLLELDS N N N N
ZM135M.PL10a PV C 2 AY424079 EKDLLALDS N N N N
ZM53M.PB12 PV C 2 AY423984 EKDLLALDS N N N N
93MW965.26 PV C 1 U08455 EKDLLALDS N N
96ZM651.02 PV C 2 AF286224 EKDLLALDS N N N
ZM 109F.PB4 PV C 2 AY424138 EKELLALNK N N
Neutralization activities of 2H10, bivalent 2H10, W100A mutant bi-2H10 and as a control 2F5 were determined against the indicated viruses. The type, clade, tier and the
accession code of the envelope protein sequence are given for each virus strain. The wild-type bi-2H10s are named bi-15GS and bi-17GS and have a 15 and 17 residue
linker respectively. The W100A mutant bi-2H10 is named W100A bi-15GS and has a 15 residue linker. The column labeled Tier indicates whether the virus is classified for
1,2, or 3 assessment of neutralizing antibodies [116]. The column labeled Epitope sequence, shows the sequence that aligns with the part of the HBX2 sequence to
which 2H10 is directed. The underlined, boldfaced residues are essential for the binding of 2H10 and are equal to the residues at the equivalent positions in HXB2,
which was used for immunization. Residues in grey are at the position of an essential residue, but deviate from the HBX2 equivalent. N indicates IC50.50 mg/ml; the
empty cells represent non-performed measurements.
doi:10.1371/journal.ppat.1003202.t001
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epitope (EQELLELDK) that partially overlaps with the 2F5
epitope [20,24] and binds to its epitope present in various Env
conformations with low nanomolar affinity.
One hypothesis is that neutralizing antibodies directed against
MPER target epitopes that are only transiently exposed during the
entry process [60,104]. Consequently their binding to the native
Env structure may be weak, as demonstrated for mAb 2F5, which
interacts only with few Env gp140 oligomers [60] and the absence
of significant binding of MPER antibodies to membrane-anchored
Env with the exception of 10E8 [9]. Because neither monomeric
2H10 nor bi-2H10 interacted with cleaved or uncleaved JR-FL
Env, we hypothesize that their target is an Env conformation
induced by receptor binding. In contrast 2H10 binds to
recombinant Env gp140 derived from strain 92UG037. Binding
of 2H10 is best described by a two-state reaction of a low affinity
contact followed by a high affinity interaction. Thus 2H10 may
induce its epitope in the soluble version of gp140, which may be
facilitated by the fact that the C-terminal end of this recombinant
gp140 protein is not constrained by the transmembrane region.
Due to the potentially transient nature of the 2H10-epitope
exposure, we tested binding to a soluble form of the fusion
intermediate conformation of gp41, gp41INT [108]. SPR measured
a 30 nM affinity for 2H10 binding to gp41INT, which is
approximately 30 times lower than the 2F5 Fab affinity for the
fusion intermediate conformation of gp41 from strain 92UG037,
92UG-gp41-inter-Fd [60]. Bi-2H10 showed a more than tenfold
increase in binding to gp41INT, but still a lower affinity when
compared to the KDs of Fab or scFv interactions of 2F5 and 4E10
with 92UG-gp41-inter-Fd [60]. It is thus possible that the lower
affinity of monovalent 2H10 for gp41INT may affect its neutral-
ization capacity of any of the tested HIV-1/SHIV strains.
However, increasing the affinity by an increased avidity as
demonstrated for bi-2H10 led to the neutralization of selected
strains including some Tier 2 viruses with IC50 values ranging
from 0.2 to 49 mg/ml, when using the stringent TZM-bl cell assay.
Figure 5. Crystal structure of 2H10 and NMR analysis of 2H10
interaction with the gp41 peptide. A) Ribbon representation of
2H10. CDR 1, 2 and 3 are colored blue, yellow and green, respectively.
Residues implicated in gp41 interaction by mutagenesis are shown as
sticks. W100 at the tip of CDR3 is required for neutralization. B) Selected
region of the 15N HSQC spectra (see Fig. S3) recorded on a 13C,15N
labeled 2H10 sample. Increasing concentrations of the gp41 peptide
were titrated into the 2H10 solution and induced specific chemical
shifts; spectra were recorded with a protein:peptide ratio of 1:0, in grey,
1:0.5 in blue and 1:1 in red.C) Chemical shift perturbations (CSPs) were
mapped onto the 2H10 structure. Residues showing 15N,1H chemical
shift perturbations greater than 0.15 ppm are shown in red and
residues with an amide resonance disappearing in the free or the
bound form are colored in green.
doi:10.1371/journal.ppat.1003202.g005
Figure 6. Surface plasmon resonance affinity measurements
reveal essential and non-essential 2H10 residues for gp41
interaction. A) 2H10 single domain mutants. The curves are labeled
with the mutant codes in colors corresponding with the colors of the
curves. The mutants R56A, R96A, E98A and R100A do not bind at all to
gp140-92UG037. Fitting the curves with the two-state reaction
algorithm yielded KDs of 8.0 nM for 2H10 WT and 10.1 nM for 2H10-
W100A. The other fits, except for those of the non-binding mutants,
yielded KDs between 5.5 nM for 2H10-S29F and 18.7 nM for 2H10-R71S
B) bi-2H10-W100A mutant and wild type bi-2H10 on immobilized
gp140-92UG037. Because the maximum responses units are slightly
different for the two bi-2H10 molecules, the curves were normalized to
the maximum response, to be able to compare the dissociation rates
well.
doi:10.1371/journal.ppat.1003202.g006
HIV-1 Neutralizing Anti-gp41 VHH
PLOS Pathogens | www.plospathogens.org 11 March 2013 | Volume 9 | Issue 3 | e1003202
Bi-2H10 may achieve HIV-1 entry inhibition by binding two gp41
molecules from the same trimer or cross link two gp41 trimers.
The crystal structure of the 2H10 VHH highlighted the longer
than usual CDR3 that displays a solvent exposed tryptophan
(W100) at its tip. Mutagenesis showed that W100 is not required
for interaction with gp41INT or gp140. However, bi-2H10 with a
W100A mutation either no longer neutralized or showed a largely
reduced neutralization potency (increases of IC50 values ,6- and
4-fold) against Tier 1 and Tier 2 strains despite its wild-type-like
interaction with gp41INT. The presence of W100 in the CDR3 of
2H10 is reminiscent of hydrophobic determinants within the
CDR3 H3 regions of mAbs 2F5 and 4E10, which are not required
for gp41 interaction, but are important for neutralization activity
[48–50]. In case of mAb 2F5, single Ser substitutions resulted in a
15- to 500-fold reduction in neutralization potency, while double
mutations to Ser completely abrogated 2F5-mediated neutraliza-
tion [50]. Even though most HIV-1 strains were no longer
neutralized by the bi-2H10 W100A mutant, it is conceivable that a
W100 to Ser mutation may have been even more efficient in
affecting neutralization due to the polar propensity of Ser.
Similarly, single mutations in the CDR3 of mAb 4E10 reduced
its neutralization potency [48] and it was noted that Asp
substitutions exerted a greater effect on neutralization potency
than Ala substitutions [49]. The effect of the bi-2H10 W100A
mutant also suggests that neutralization by bi-2H10 is not solely
due to heteroligation of two antigen binding domains via an
increased avidity [59,109]. We therefore propose that CDR3
W100 plays a crucial role in neutralization by bi-2H10, which
resembles the role of the hydrophobic CDR3 of mAbs 2F5 and
4E10 in neutralization.
Numerous studies suggested that the hydrophobic CDR3 residues
are implicated in lipid/membrane interaction thereby facilitating
Table 2. Data collection and refinement statistics.
Space group I23
Cell dimensions a, b, c (A˚) 89.95, 89.95, 89.95
Wavelength (A˚) 0.9395
Resolution (A˚) 25.00–1.3 (1.3–1.37)
Measured reflections 3427903
Unique reflections 38741
Rmerge 0.069 (0.295)
I/sI 6.1 (2.2)
Completeness (%) 99.0 (100.0)
Redundancy 13.9 (14.2)
Wilson B factor (A˚2) 12.2
Rcryst (Nu reflections) 0.14 (29381)
Rfree (Nu reflections) 0.17 (1509)
No. atoms Protein 4960
Water 172
B-factors Protein 32.32
Water 33.89
R.m.s deviations Bond lengths (A˚) 0.005
Bond angles (u) 1.09
Numbers in parentheses refer to the highest resolution shell. Rmerge =S|I _ ÆIæ|/
ÆSIæ, where I = observed intensity. Rcryst =S|Fo _ Fc|/S|Fo|, where |Fo| = observed
structure factor. Amplitude and |Fc| = calculated structure factor amplitude. Rfree
is Rcryst for 3% of reflections excluded from the refinement.
doi:10.1371/journal.ppat.1003202.t002
Figure 7. Molecular modeling of the 2H10-gp41 peptide
interaction suggests that 2H10 W100 is oriented towards the
membrane. A) Molecular model of the gp41 peptide interaction with
2H10 produced by HADDOCK. Salt bridges and hydrogen bonds
present in the top model and found in most of the top10 models are
shown as dashed lines. B) Superpositioning of the Ca atoms of the
gp41 peptide derived from the HADDOCK 2H10-peptide model onto
the structure of a late fusion intermediate of gp41 [29] shows that the
CDR3 W100 is oriented towards the membrane and found in the same
plane as gp41 residues W678, W680 and Y681. Note that there are no
clashes between the 2H10 VHH and gp41.
doi:10.1371/journal.ppat.1003202.g007
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antigen binding [46,110,111]. One possibility is that MPER itself
becomes membrane-embedded during the fusion reaction and
MPER-specific antibodies need to recognize their epitope within the
membrane context [52,112]. We therefore presented MPER in a
lipid bilayer context to allow selection of antibodies that can
recognize lipid and protein determinants. However, despite the
presence of W100 in CDR3, 2H10 as well as the control mAb 2F5
did not show any detectable lipid binding specificity in vitro.
All HIV-1 strains that were neutralized by bi-2H10 have the
epitope sequence determined by pepscan analyses except for
92UG037.A9 which has Q658 replaced by a lysine. However,
SPR measurements of 2H10 to gp140 env derived from
92UG037.A9 corroborate 2H10 binding. The discrepancy may
be explained by the use of cyclic peptides in the pepscan analysis,
which showed a lower affinity in the ITC experiment. Therefore a
Q658K exchange may have had a larger effect on binding within
the cyclic version than within natural contexts of the epitope.
Sequence analysis of 2300 Env sequences revealed that ,28%
have the epitope 657-E(Q/K/H)-XX-LE-XX-K-665. Consider-
ing only B clades, the number of isolates covered would rise to
,61%. In comparison, 2F5 and 4E10 have been shown to
neutralize 68% and 97% of all clade B strains tested and 60% and
98% of all clades, respectively [1].
The combined structural approach using peptide modeling,
NMR, docking and mutagenesis showed that 2H10 interacts with a
helical linear gp41 epitope. VHH maturation played an important
role in optimizing antigen binding, because somatic mutations
involve both CDR and framework residues at the interaction site.
High framework mutation rate has been observed in broadly
neutralizing human antibodies as well [5–7,113]. The helical
epitope conformation is present in the late fusion intermediate
conformation of gp41, gp41528–683 [29] that interacts with 2H10.
This is unexpected, because 4E10 whose epitope is exposed and
accessible in gp41528–683 [29] does not interact with this conforma-
tion due to molecular clashes of the light chain with gp41 heptad
repeat region 1 [29]. The fact that the small size of 2H10 allows
binding to gp41528–683 may constitute a disadvantage for using small
llama VHH over complete antibodies; the VHH may thus less
efficiently prevent refolding of gp41 into the six helical bundle post
fusion conformation. Nevertheless, an interesting feature surfaced
from the 2H10-gp41528–683 complex model. The model poses 2H10
CDR3 W100 in the same plane as gp41 MPER residues W678,
W680 and Y681, which may insert into the membrane during the
fusion process [29]. This indirectly corroborates the hypothesis that
the necessity of W100 for HIV-1 neutralization is in agreement with
the suggestion that part of MPER may be membrane embedded.
Because MPER, as observed in the late fusion-intermediate
gp41528–683 structure, may be already membrane-embedded at an
earlier stage, anti-MPER antibodies such as 2H10 may act much
earlier to block the fusion process. Alternatively, bi-2H10 binding
may prevent membrane extraction of MPER, which is likely
required to finalize membrane fusion [29].
The epitope of 2H10 overlaps with the helical epitope of mAb
13H11, which is, however, non-neutralizing due to the absence of
a long hydrophobic heavy chain CDR3 [114]. The helical epitope
of 2H10 is part of the helical epitope recognized by the broadly
neutralizing anti-MPER mAb 10E8, isolated from a patient [9]. In
this MPER conformation, which may represent the structure of
MPER within native Env trimers, residues 656 to 683 form two
short L-shaped helices of which the C-terminal helix provides most
antibody binding contacts. Most notably, mAb 10E8 employs
hydrophobic CDR3 residues Phe 100A and W100B for interaction
with its epitope. Because mAb 10E8 displays no autoreactivity it
presents a new class of potent anti-MPER antibodies [9].
The VHH 2H10, which was elicited by gp41 proteoliposomes
as antigen stresses the importance of a membrane component in
generating anti-MPER neutralizing antibodies. Although there
have been many attempts to generate neutralizing MPER-specific
anti gp41 antibodies in animals, no protein-based immunization
scheme has produced sera or antibodies that neutralized HIV-1 in
the stringent TZM-bl assay [16,17,107]. In this study, we have
demonstrated that it is possible to elicit anti-MPER antibodies that
neutralize HIV-1 by employing proteoliposomes containing the
native Env transmembrane region that may orient MPER
optimally with respect to the lipid bilayer, which in turn is
important for antibody neutralization [55]. Although bi-2H10
lacks the potency and breadth of 2F5, 4E10 or 10E8, optimization
of the immunization protocol such as longer immunization
schemes which may produce more extensive somatic mutations
could yield antibodies with higher breadth and potency.
Supporting Information
Figure S1 SPR with 2H10 and bi-2H10. The following
ligands were immobilized on a were immobilized on a CM5 chip:
gp41INT A), B) and H), gp41528-683 C) and D), and gp140-
92UG037 E), F) and G). Injections were performed with a range of 1
to 200 nM for 150 seconds each on both gp41 constructs, while for
the immobilized gp140-92UG037, 6.25, 25, 100 and 400 nM for
60 seconds was used. The fitted curves are represented by black
lines and the raw data are shown in color. The data were measured
in triplicates and the curves superpose very well. A) Response for
2H10on gp41INT, fitted with separate association and dissociation
(shown association fit). B) Response for bi-2H10 on gp41INT. The
curves were fitted using 1:1 Langmuir model. C), D). Response for
2H10 and bi-2H10 on gp41528-683 fitted using 1:1 Langmuir
model. E) Proof of two-state reaction of 2H10 binding to gp140 on
gp140-92UG037. Injections were performed with 100 nM 2H10
with different injection durations. The curves were normalized to
the maximum of obtained response units. The observation that the
dissociation is dependent on injection duration indicates a two-state
reaction binding. F) Response for 2H10 on gp140-92UG037. The
curves were fitted with the two-state reaction algorithm. G)
Response for bi-2H10 on gp140-92UG037. The curves were fitted
with the heterogeneous ligand algorithm. H) Response for mutant
2H10-W100A on gp41INT, fitted with separate association and
dissociation (shown association fit).
(TIF)
Figure S2 Lipid binding test of 2H10, 4E10 and 2F5. A)
Sucrose gradient centrifugation analyses of 2H10, 4E10 and 2F5.
The top and bottom of the gradient are indicated; hc, heavy chain;
lc, light chain. B) ELISA with cardiolipin and phosphatidylserine.
Binding of 4E10, 2F5, 2H10 and bi-2GH10 are indicated. Left panel
binding to cardiolipin; right panel, binding to posphatidylserine.
(TIF)
Figure S3 15N HSQC of 2H10 without and with a 1.5-
fold excess of peptide. The spectra were acquired at
600 MHz, T = 37 C. Protein concentration was 0.95 mM, in in
25 mM HEPES buffer and 75 mM NaCl (pH 6.7).
(TIF)
Figure S4 Secondary structure propensity of the free
and bound form of 2H10 determined from CB, CA, CO,
N chemical shift analysis using the program TALOS+.
The chemical shift index (CSI) value of 1 corresponds to 100%
helical conformation propensity and a value of 21 corresponds to
a 100% b-strand conformation propensity.
(TIF)
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Figure S5 Histograms showing the value of the chem-
ical shift difference (CSD) in 2H10 induced upon binding
with the gp41 peptide (1.5 fold excess). Residue numbers
are indicated on the X axis (residues for which CSD is missing are
prolines. The green and pale green bars with an arbitrary height
represent residues whose NH correlation is not present in the 15N-
HSQC spectrum for the free and bound form of 2H10,
respectively (probably because of conformation exchange broad-
ening). The CSI analysis of the free and bound form of 2H10 show
that upon addition of an excess of ligand, the secondary structure
of the protein does not change.
(TIF)
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